StonvexLoading…
StonvexStonvexStonvexCore line items from CME's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.88B | $6.52B | $4.87B | $3.33B |
Operating Income | $1.31B | $4.23B | $3.21B | $2.24B |
Net Income | $1.15B | $4.07B | $2.89B | $1.98B |
EPS (Diluted) | $3.18 | $11.16 | $7.92 | $5.43 |
Total Assets | $201.99B | $198.42B | $187.14B | $179.91B |
Total Liabilities | $175.38B | $169.70B | $158.95B | $152.17B |
Cash & Equivalents | $2.39B | $4.42B | $2.45B | $1.98B |
Free Cash Flow OCF − CapEx | $1.24B | $4.19B | $3.09B | $2.14B |
Shares Outstanding | 363.21M | 360.31M | 360.33M | 360.30M |